07 Jan 2001

Rhinomer® 1 (Rhinomer® 1 (Soft)/-2 (Medium)/-3 (Intensiv) Lösung) - Deutschland

Updated: 07 Jan 2001

Rhinomer® 1 (Soft) | -2 (Medium) | -3 (Intensiv)

Rhinomer 1 (Soft): Reinigung u. sanfte Spülung d. Nasenhöhle, z. B. als begleitende Maßnahme b. Schnupfen. Anw. auch für Sgl. u. Kleinkdr. Zum Anfeuchten d. Nasenschleimhaut (z. B. b. geringer Luftfeuchtigkeit in geheizten od. klimatisierten Räumen), Reinigung d. Nasenhöhle b. vermehrter Luftbelastung (z. B. Staub etc.). Für jede Altersgruppe. Rhinomer 2 (Medium): Reinigung d. Nasenhöhle, z. B. zum Lösen v. Krusten, Anw. vor u. nach Nasenoperationen, b. vermehrter Luftbelastung (z. B. Staub etc.), als begleitende Maßnahme b. Schnupfen. Für Kdr. ab 2 J. u. Erw. Rhinomer 3 (Intensiv): Intensive Reinigung d. Nasenhöhle, z. B. zum Lösen von Krusten, Anw. vor u. nach Nasenoperationen, begleitende Maßnahme bei Schnupfen. Für Kdr. 6 J. u. Erw.

Rhinomer® 1 Description, Presentation and Dosage

Rhinomer® 1 Description

Rhinomer® 1 Drug Class Description

Andere Stoffe

Rhinomer® 1 Drug Description

1 ml enth.: steriles, isotonisiertes Meerwasser entspr. einer 0,9%igen NaCl-Lsg.

Rhinomer® 1 Generic Name

Rhinomer® 1 (Soft)/-2 (Medium)/-3 (Intensiv) Lösung

Rhinomer® 1 Presentation

Rhinomer® 1 Presentation

Rhinomer® 1 (Soft)/-2 (Medium)/-3 (Intensiv)

Rhinomer® 1 Manufacturer

Novartis Consumer Health

Related Learning Zones

Anti-Coagulation Video Channel

Anti-Coagulation Video Channel

The Anti-Coagulation Video Channel is regularly updated with expert videos discussing how to prevent stroke and systemic embolism in non-valvular atrial fibrillation (AF) patients and how to prevent and treat venous thromboembolism (VTE). This free resource is intended for primary care practitioners and specialists involved in the treatment and follow up care of patients with AF or VTE.

This resource has been developed in collaboration with Boehringer Ingelheim.

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis is intended for healthcare professionals involved in the treatment and management of patients with psoriasis. This resource has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A. Users can expect to find sections containing expert videos, clinical slide decks, congress highlights, key publications and links to useful resources.

This resource has been developed in collaboration with Novartis Pharma AG.

Rhinomer® 1 Dosage

Rhinomer® 1 Adult Dosage

keine.

Rhinomer® 1 Precautions, Reactions and Contraindications

Rhinomer® 1 Special Precautions

Rhinomer® 1 Special Precautions

Rhinomer 2: Kdr.

Related Drugs - Ear, Nose and Throat

Back to top